GSK481 is primarily used in pharmaceutical research as a potent and selective inhibitor of the enzyme PI3Kδ (phosphoinositide 3-kinase delta). This enzyme plays a key role in immune cell signaling, making GSK481 a valuable tool in studying inflammatory and autoimmune diseases such as rheumatoid arthritis, asthma, and lupus. It has also shown potential in oncology research, particularly in B-cell malignancies like chronic lymphocytic leukemia, where PI3Kδ signaling contributes to tumor cell survival and proliferation. Due to its high selectivity, GSK481 helps minimize off-target effects in experimental models, supporting its use in preclinical studies to validate PI3Kδ as a therapeutic target.